Ask AI
ProCE Banner Activity

Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

Podcast Episodes

In this podcast, experts discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting.

Released: July 30, 2025

Expiration: January 29, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Disclosure

Primary Author

Kevin Kalinsky, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Gilead, Puma Biotechnology, Seattle Genetics.

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Artios, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Blueprint Medicines, Bicycle Therapeutics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb/Systimmune, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Roche, Samsung Bioepis, Sumitovant Biopharma, Summit, Tango, Zuellig; researcher: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvinas, Gilead, Jazz, Lilly, Pfizer, Roche.